VRCDF (Verici Dx) Debt-to-Equity : 0.05 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Debt-to-Equity?

Verici Dx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.18 Mil. Verici Dx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.27 Mil. Verici Dx's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $9.86 Mil. Verici Dx's debt to equity for the quarter that ended in Jun. 2024 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Verici Dx's Debt-to-Equity or its related term are showing as below:

VRCDF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.08 Max: 0.15
Current: 0.05

During the past 4 years, the highest Debt-to-Equity Ratio of Verici Dx was 0.15. The lowest was 0.05. And the median was 0.08.

VRCDF's Debt-to-Equity is ranked better than
81.68% of 191 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.26 vs VRCDF: 0.05

Verici Dx Debt-to-Equity Historical Data

The historical data trend for Verici Dx's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Debt-to-Equity Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.06

0.15

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial			-	0.06	0.09	0.15	0.05

Competitive Comparison of Verici Dx's Debt-to-Equity

For the Diagnostics & Research subindustry, Verici Dx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Verici Dx's Debt-to-Equity falls into.

Verici Dx Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Verici Dx's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.163	+	0.377)	/	3.558
	=	0.15

Verici Dx's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.184	+	0.274)	/	9.861
	=	0.05

Verici Dx (OTCPK:VRCDF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Verici Dx Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Verici Dx's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines